In 2012, Universal DX was born from a powerful realization: cancer could be transformed from a deadly disease into a curable one if only we could detect it early enough. The founders saw a critical gap in cancer diagnostics - traditional screening methods were invasive, inconvenient, and often detected cancer too late. They envisioned a future where a simple blood test could reveal cancer's earliest signals, when treatment options are most plentiful and survival rates are highest.
Starting with deep expertise in multi-omics, computational biology, and machine learning, the team set out to "crack cancer's code" in the blood. They built a technological platform capable of reading the subtle molecular signals that cancer cells shed into the bloodstream. Their first breakthrough, Signal-C®, is a liquid biopsy test that accurately detects colorectal cancer with 93% sensitivity and 92% specificity, even identifying precancerous lesions. Now, with headquarters spanning Madrid, Ljubljana, Cambridge, and Dallas, and a strategic collaboration with Quest Diagnostics, Universal DX is expanding their multicancer platform to detect other high-burden cancers, bringing them closer to their ambitious mission: a future where cancer is not just treatable, but preventable and curable.